hVivo grows on positive vaccine testing news

Shares in AIM-listed drug discovery outfit hVivo (LON:HVO) were up by 30.96% at 25p at 13:45 BST after the company announced positive results from Phase IIb field testing. The firm has been developing a new universal influenza vaccine candidate and the latest tests show a reduction in infection rates and severity in subjects. with the treatment being well tolerated in line with prior studies.

Get the latest from Master Investor directly in your inbox – Sign-up HERE for FREE

Management believe that they are ready to move ahead to phase III trials and Executive Chairman Trevor Phillips said that the “market potential for a broad spectrum universal influenza vaccine is significant“.